On Sept. 15, 2020, Vaxess Technologies and Medigen Vaccine Biologics (MBV) announced a partnership to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system.

The vaccine in development uses a stabilized form of the spike protein (S-2P) from the SARS-CoV-2 virus. This immunogen was co-developed by researchers at the U.S. National Institutes of Health, and the University of Texas at Austin.